Navigation Links
Solos Endoscopy, Inc. Reports $90,005 in Sales Revenue for Fourth Quarter 2010
Date:1/27/2011

BOSTON, Jan. 27, 2011 /PRNewswire/ -- Solos Endoscopy, Inc. (OTCPK: SNDY) is pleased to announce that the Company generated revenues during the three months ended December 31, 2010 in the amount of $90,005. The revenue for the three month period is a result of instrument sales to over fifty Hospitals, Clinics, Healthcare Centers, Medical Centers and Surgery Centers across the United States.

Solos looks towards continued growth in 2011 through new product development, new product sales and the completion of the requirements for the Company's ISO 13485 quality management system (QMS) initiative. The ISO QMS initiative is a major step in obtaining the CE Mark and the permission to sell medical devices in the European Union. Solos recently announced the approval of its 2011 recapitalization plan, which allows greater flexibility to utilize the assets of the Company to raise the necessary capital to achieve the aforementioned goals.

"As an innovative HealthCare instrument company, Solos continues to position itself to take advantage of the ever increasing demand of the medical industry," stated Bob Segersten, President of Solos Endoscopy, Inc. "Our portfolio is centered on instruments like the MammoView Breast Endoscopy System that are designed to support a wide range of options from screening and diagnosis, to treatment and management of medical conditions."

The Company expects to post its full unaudited financial results for the three months ended December 31, 2010 on the OTC Markets Group website within in the next sixty days.

About Solos Endoscopy, Inc.:

Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions. Additional information on its FDA approved products is available on the Company's website at: www.solosendoscopy.com.

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.

.


'/>"/>
SOURCE Solos Endoscopy, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Solos Endoscopy, Inc. Trends toward Strong Continued Growth in 2011
2. Solos Endoscopy, Inc. Announces Recapitalization Plan for 2011
3. Solos Endoscopy, Inc. Revenue Grows 34.8% for Third Quarter 2010
4. Solos Endoscopy, Inc. Announces Results of 2010 Annual Shareholder Meeting
5. Solos Endoscopy, Inc. to Hold Annual Shareholder Meeting September 28, 2010
6. Solos Endoscopy, Inc. Develops Relay Lense Adapter System For MammoView® Product Line
7. Solos Endoscopy, Inc. Increases Revenues by 10 Percent for First Quarter 2010 as Compared to First Quarter 2009
8. Solos Endoscopy, Inc. Appoints Experienced CFO To Financial Leadership Amidst Growth
9. Solos Endoscopy, Inc. Granted U.S. Trademark for MammoView(R)
10. Solos Endoscopy, Inc. Set To Develop European Union Conforming CE Mark Technical File
11. Solos Endoscopy, Inc. Set To Develop New Polymer Dilator For MammoView(TM) System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... Divoti USA will engrave and process all non-coated stainless ... FDA requirements, which stipulates new criteria regarding medical device manufacture and ... ID jewelry such as Medical ID Bracelets, can rest assured that ... the new FDA requirements . ... Divoti offers this dark mark fiber laser engraving process with ...
(Date:10/11/2017)... , Oct. 11, 2017  BioPharmX Corporation (NYSE MKT: ... that developed an innovative way to use nonlinear optical ... delivery of new drugs. ... Dermatology Conference will show how researchers from BioPharmX and ... Medical School used a suite of imaging techniques in ...
(Date:10/11/2017)...  True Health, a leader in integrated diagnostics ... National Breast Cancer Awareness month to educate doctors ... Research recently published in ... than 10 million American women are at significant ... BRCA2 and have not had testing. These mutations can ...
Breaking Medicine Technology:
(Date:10/13/2017)... Nevada (PRWEB) , ... October 13, 2017 , ... ... Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil ... required and providing a CBD form that can be easily incorporated into liquid products, ...
(Date:10/13/2017)... Calif. (PRWEB) , ... October 13, 2017 , ... Many ... dementia. However, many long-term care insurance companies have a waiver for care if the ... 90-day elimination period, when the family pays for care, is often waived, so the ...
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released a ... books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture of ... have tossed it off as mere rubbish, but Yisrayl Hawkins says that is because ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the ... published author, William Nowers. Captain Nowers and his wife, Millie, have six children, ... in the Navy. Following his career as a naval aviator and carrier pilot, ...
(Date:10/12/2017)... ... October 12, 2017 , ... The ... demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, ... to meet the highest standard. , These products are also: Gluten Free, ...
Breaking Medicine News(10 mins):